Zinc Chemoprevention of Arsenic Co-Carcinogenesis
锌对砷协同致癌作用的化学预防
基本信息
- 批准号:8762020
- 负责人:
- 金额:$ 31.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-01 至 2019-08-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAddressAdverse effectsAffinityAntioxidantsArsenicArsenitesBase Excision RepairsBenzo(a)pyreneBerylliumBindingBiochemicalBiological AssayCadmiumCarcinogensCellsChemopreventionChemoprotectionChemoprotective AgentChromiumCoupledCysteineDNA BindingDNA Binding DomainDNA DamageDNA RepairDNA Repair InhibitionDNA Repair PathwayDNA repair proteinEmployee StrikesEpidemiologyFoodFoundationsGene MutationGenomicsGoalsHumanIntakeMalignant neoplasm of lungMalignant neoplasm of urinary bladderMeasuresMetalsMethodsMolecular TargetMusMutagenesisNucleotide Excision RepairOutcomeOutcome StudyPathway interactionsPlayPoly(ADP-ribose) PolymerasesPopulationPrevention strategyProteinsPublishingRadiation Induced DNA DamageReportingResearchRiskRoleSimulateSkinSkin CancerSkin CarcinogenesisSkin NeoplasmsSmokingSoilSolidSun ExposureTestingUV inducedUltraviolet RaysWaterWorkXPA geneXeroderma PigmentosumZincZinc Fingersbasecarcinogenesiscostenzyme activityepidemiologic dataexposed human populationfunctional restorationimprovedin vivoinnovationnoveloxidative DNA damagepreventpublic health relevancerepairedresearch studysynergismsynthetic peptidetumorigenesis
项目摘要
DESCRIPTION (provided by applicant): There is strong evidence that in addition to the known direct carcinogenic actions of high arsenic concentrations, low, non-carcinogenic levels of arsenic synergize with other DNA-damaging agents such as benzo[a]pyrene and ultraviolet radiation (UVR) to enhance carcinogenesis. This observation has led to the identification of arsenic as a co-carcinogen. One mode of action to account for arsenic co-carcinogenesis is inhibition of DNA repair proteins containing zinc finger DNA binding motifs. Research from our lab demonstrates that: i) zinc finger proteins with e3 cysteine residues are direct molecular targets for arsenite binding, including xeroderma pigmentosum group A (XPA) and poly(ADP-ribose)polymerase (PARP)-1, which are the critical proteins for nucleotide excision repair (NER) and base excision repair (BER) respectively; ii) low levels of arsenite enhance UVR-induced photoproducts and oxidative DNA damage; and iii) supplemental zinc prevents arsenite effects on PARP-1 inhibition, enhancement of UVR-induced DNA damage and mutations. We hypothesize that zinc supplement will prevent arsenite enhancement of UVR-induced skin tumors by restoring the DNA repair capabilities in both BER and NER pathways. The proposed study will address a novel mechanism by which zinc may act to prevent arsenic-augmented carcinogenesis through interaction with distinct molecular targets in DNA repair pathways. In Aim 1, we will use multiple analytical approaches to definitively examine the competitive interaction of arsenite and zinc with synthetic peptides representing the PARP-1 and XPA zinc finger domains and with purified protein. These findings will be coupled with functional assays to establish the consequences of any identified differences in arsenite affinity for target proteins and zinc interactions. Aim 2 will analyze PARP-1 and XPA isolated from treated cells to measure arsenic and zinc binding to protein and the corresponding functional consequences to reveal the specific mechanism by which zinc reverses the arsenic effects. In Aim 3, we will validate PARP-1 and XPA as arsenic targets in vivo using biochemical methods, and test the hypothesis that zinc will prevent arsenic enhancement of UVR-induced DNA damage and skin tumors. The outcomes from the proposed studies are expected to demonstrate the capability of zinc to restore PARP-1 and XPA activity leading to improved genomic integrity and a decrease in the arsenic contribution to co-carcinogenesis. Although zinc has been considered chemoprotective largely through its reported general antioxidant activities, this proposal is innovative by focusing on a novel mechanism by which zinc prevents arsenite binding with specific zinc finger DNA repair protein targets, thus reversing the arsenite inhibition of DNA repair. This study will provide the solid foundations for a clear mechanistic understanding of how supplemental zinc reduces arsenic co-carcinogenesis, and provide the proof of principle for the potential of zinc supplement to prevent arsenic co-carcinogenesis. If validated, supplemental zinc could represent a low cost and easily implemented strategy for chemoprevention in arsenic exposed populations.
描述(由申请人提供):有强有力的证据表明,除了已知的高浓度砷的直接致癌作用外,低水平、非致癌水平的砷还与其他DNA损伤剂,如苯并[a]芘和紫外线辐射(UVR)协同作用,促进致癌。这一观察结果导致确定砷是一种共同致癌物质。解释砷共同致癌的一种作用模式是抑制含有锌指DNA结合基序的DNA修复蛋白。我们实验室的研究表明:i)带有E3半胱氨酸残基的锌指蛋白是亚砷酸盐结合的直接分子靶点,包括A组干皮病(XPA)和多聚ADP核糖聚合酶(PARP)-1,它们分别是核苷酸切除修复(NER)和碱基切除修复(BER)的关键蛋白质;ii)低水平的亚砷可以增强紫外线诱导的光产物和DNA氧化损伤;以及iii)补充锌可以阻止亚砷对PARP-1的抑制作用,增强UVR诱导的DNA损伤和突变。我们假设补锌可以通过恢复BER和NER通路的DNA修复能力来阻止亚砷酸盐对UVR诱导的皮肤肿瘤的增强。这项拟议的研究将探讨一种新的机制,即锌可能通过与DNA修复途径中不同的分子靶点相互作用来防止砷增强的癌症发生。在目标1中,我们将使用多种分析方法来明确地研究亚砷酸盐和锌与代表PARP-1和XPA锌指结构域的合成肽以及与纯化蛋白的竞争性相互作用。这些发现将与功能分析相结合,以确定亚砷酸盐对靶蛋白和锌相互作用亲和力的任何已识别差异的后果。目的2分析从处理细胞中分离出的PARP-1和XPA,以测定砷和锌与蛋白质的结合及其相应的功能后果,以揭示锌逆转砷效应的具体机制。在目标3中,我们将使用生物化学方法在体内验证PARP-1和XPA作为砷的靶点,并验证锌可以防止砷增强UVR诱导的DNA损伤和皮肤肿瘤的假设。拟议研究的结果有望证明锌恢复PARP-1和XPA活性的能力,从而改善基因组完整性,减少砷对共同致癌的贡献。虽然锌主要通过其一般的抗氧化活性被认为具有化学保护作用,但这一建议是创新的,它专注于一种新的机制,通过该机制,锌可以阻止亚砷酸盐与特定的锌指DNA修复蛋白靶标结合,从而逆转亚砷酸盐对DNA修复的抑制。本研究将为明确补锌如何降低砷共癌的发生机制提供坚实的基础,并为补锌预防砷共癌的潜力提供理论依据。如果得到验证,补充锌可以代表一种低成本和易于实施的策略,用于砷暴露人群的化学预防。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LAURIE G HUDSON其他文献
LAURIE G HUDSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LAURIE G HUDSON', 18)}}的其他基金
Illuminating the functions and translational potential of CDC42BP/MRCK kinases in ovarian cancer
阐明 CDC42BP/MRCK 激酶在卵巢癌中的功能和翻译潜力
- 批准号:
10216717 - 财政年份:2021
- 资助金额:
$ 31.33万 - 项目类别:
Mutational Signatures of a Combined Environmental Exposure: Arsenic and Ultraviolet Radiation
综合环境暴露的突变特征:砷和紫外线辐射
- 批准号:
10844717 - 财政年份:2020
- 资助金额:
$ 31.33万 - 项目类别:
Mutational Signatures of a Combined Environmental Exposure: Arsenic and Ultraviolet Radiation
综合环境暴露的突变特征:砷和紫外线辐射
- 批准号:
10330581 - 财政年份:2020
- 资助金额:
$ 31.33万 - 项目类别:
Biomarkers and mechanisms of metal and mixed metal exposures
金属和混合金属暴露的生物标志物和机制
- 批准号:
10707512 - 财政年份:2017
- 资助金额:
$ 31.33万 - 项目类别:
Biomarkers and mechanisms of metal and mixed metal exposures
金属和混合金属暴露的生物标志物和机制
- 批准号:
10353202 - 财政年份:2017
- 资助金额:
$ 31.33万 - 项目类别:
Zinc Chemoprevention of Arsenic Co-Carcinogenesis
锌对砷协同致癌作用的化学预防
- 批准号:
9325454 - 财政年份:2014
- 资助金额:
$ 31.33万 - 项目类别:
Arsenic co-carcinogenesis with UVR: nitrosation and oxidation of target proteins
砷与 UVR 的协同致癌作用:目标蛋白的亚硝化和氧化
- 批准号:
8856568 - 财政年份:2012
- 资助金额:
$ 31.33万 - 项目类别:
Capitalizing on NSAID enantiomer selectivity for cancer prevention and therapy(PQ
利用 NSAID 对映体选择性进行癌症预防和治疗 (PQ
- 批准号:
8625502 - 财政年份:2012
- 资助金额:
$ 31.33万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 31.33万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 31.33万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 31.33万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 31.33万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 31.33万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 31.33万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 31.33万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 31.33万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 31.33万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 31.33万 - 项目类别:
Research Grant














{{item.name}}会员




